Answer
Ravulizumab binds specifically to complement protein C5, inhibiting its cleavage into C5a and C5b, the initiating subunit of the membrane attack complex, thereby preventing C5b-9 formation while preserving early complement activation components.
Sources for this answer
- Ultomiris 300 mg/3 mL and 1100 mg/11 mL PLGB 31187/0007Alexion Pharma UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated
Sources checked